# Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

> **NCT01019590** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
- **DRUG:** Benicar HCT ® Tablets 40 mg/25 mg

## Key facts

- **NCT ID:** NCT01019590
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019590, "Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01019590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*